Wave Life Sciences Ltd
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent… Read more
Wave Life Sciences Ltd (WVE) - Net Assets
Latest net assets as of September 2025: $124.55 Million USD
Based on the latest financial reports, Wave Life Sciences Ltd (WVE) has net assets worth $124.55 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($241.38 Million) and total liabilities ($116.83 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $124.55 Million |
| % of Total Assets | 51.6% |
| Annual Growth Rate | N/A |
| 5-Year Change | 131.12% |
| 10-Year Change | 36.5% |
| Growth Volatility | 2350.48 |
Wave Life Sciences Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Wave Life Sciences Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Wave Life Sciences Ltd (2013–2024)
The table below shows the annual net assets of Wave Life Sciences Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $209.51 Million | +428.68% |
| 2023-12-31 | $39.63 Million | +187.89% |
| 2022-12-31 | $-45.09 Million | -238.75% |
| 2021-12-31 | $32.50 Million | -64.15% |
| 2020-12-31 | $90.65 Million | +26.60% |
| 2019-12-31 | $71.61 Million | -2.37% |
| 2018-12-31 | $73.35 Million | -47.54% |
| 2017-12-31 | $139.81 Million | +3.67% |
| 2016-12-31 | $134.86 Million | -12.14% |
| 2015-12-31 | $153.49 Million | +7472.32% |
| 2014-12-31 | $2.03 Million | +126.11% |
| 2013-12-31 | $-7.76 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Wave Life Sciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 111121100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.18 Billion | 560.91% |
| Other Comprehensive Income | $-262.00K | -0.13% |
| Other Components | $156.45 Million | 74.67% |
| Total Equity | $209.51 Million | 100.00% |
Wave Life Sciences Ltd Competitors by Market Cap
The table below lists competitors of Wave Life Sciences Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SHOU. HLDGS. LTD. (BL)
F:SHVA
|
$1.10 Billion |
|
Guangdong Shenglu Telecommunication Tech Co Ltd
SHE:002446
|
$1.10 Billion |
|
Perella Weinberg Partners
NASDAQ:PWP
|
$1.10 Billion |
|
Indosat Tbk
JK:ISAT
|
$1.10 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
$1.10 Billion |
|
Wilhelm Wilhelmsen Holding ASA
LSE:0P0T
|
$1.10 Billion |
|
Zhejiang Windey Co Ltd
SHE:300772
|
$1.10 Billion |
|
Sinochem International Corp
SHG:600500
|
$1.10 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Wave Life Sciences Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 39,630,000 to 209,515,000, a change of 169,885,000 (428.7%).
- Net loss of 97,008,000 reduced equity.
- New share issuances of 236,176,000 increased equity.
- Other comprehensive income decreased equity by 138,000.
- Other factors increased equity by 30,855,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-97.01 Million | -46.3% |
| Share Issuances | $236.18 Million | +112.73% |
| Other Comprehensive Income | $-138.00K | -0.07% |
| Other Changes | $30.86 Million | +14.73% |
| Total Change | $- | 428.68% |
Book Value vs Market Value Analysis
This analysis compares Wave Life Sciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.22x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-2.18 | $12.46 | x |
| 2014-12-31 | $0.10 | $12.46 | x |
| 2015-12-31 | $7.12 | $12.46 | x |
| 2016-12-31 | $5.91 | $12.46 | x |
| 2017-12-31 | $5.27 | $12.46 | x |
| 2018-12-31 | $2.53 | $12.46 | x |
| 2019-12-31 | $2.11 | $12.46 | x |
| 2020-12-31 | $2.31 | $12.46 | x |
| 2021-12-31 | $0.63 | $12.46 | x |
| 2022-12-31 | $-0.57 | $12.46 | x |
| 2023-12-31 | $0.37 | $12.46 | x |
| 2024-12-31 | $1.52 | $12.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Wave Life Sciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -46.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -89.57%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.68x
- Recent ROE (-46.30%) is above the historical average (-132.32%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.54 Million |
| 2014 | -257.97% | 0.00% | 0.00x | 1.45x | $-5.43 Million |
| 2015 | -12.51% | -12631.58% | 0.00x | 1.08x | $-34.55 Million |
| 2016 | -41.08% | -3730.71% | 0.01x | 1.22x | $-68.89 Million |
| 2017 | -72.98% | -2754.72% | 0.02x | 1.30x | $-116.02 Million |
| 2018 | -199.94% | -1017.43% | 0.05x | 4.03x | $-153.99 Million |
| 2019 | -270.42% | -1211.52% | 0.06x | 3.97x | $-200.80 Million |
| 2020 | -165.37% | -746.68% | 0.07x | 3.08x | $-158.98 Million |
| 2021 | -376.16% | -298.42% | 0.20x | 6.37x | $-125.49 Million |
| 2022 | 0.00% | -4434.72% | 0.02x | 0.00x | $-157.31 Million |
| 2023 | -145.12% | -50.76% | 0.41x | 6.94x | $-61.48 Million |
| 2024 | -46.30% | -89.57% | 0.31x | 1.68x | $-117.96 Million |
Industry Comparison
This section compares Wave Life Sciences Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Wave Life Sciences Ltd (WVE) | $124.55 Million | 0.00% | 0.94x | $1.10 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |